Impax Drug Patent Portfolio
Impax owns 5 orange book drugs protected by 31 US patents with Twinject 0.15 having the least patent protection, holding only 2 patents. And Crexont with maximum patent protection, holding 16 patents. Given below is the list of Impax's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11986449 | Levodopa dosing regimen | 21 Dec, 2041 | Active |
| US12109185 | Levodopa dosing regimen | 21 Dec, 2041 | Active |
| US12194150 | Levodopa dosing regimen | 21 Dec, 2041 | Active |
| US12201596 | Levodopa dosing regimen | 21 Dec, 2041 | Active |
| US10098845 | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof | 07 Oct, 2034 | Active |
| US10292935 | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof | 07 Oct, 2034 | Active |
| US10688058 | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof | 07 Oct, 2034 | Active |
| US10973769 | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof | 07 Oct, 2034 | Active |
| US10987313 | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof | 07 Oct, 2034 | Active |
| US11357733 | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof | 07 Oct, 2034 | Active |
| US11622941 | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof | 07 Oct, 2034 | Active |
| US11666538 | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof | 07 Oct, 2034 | Active |
| US12064521 | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof | 07 Oct, 2034 | Active |
| US12128141 | Muco-adhesive, controlled release formulation of levodopa and/or esters of levodopa and uses thereof | 07 Oct, 2034 | Active |
| US12178918 | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof | 07 Oct, 2034 | Active |
| US12178919 | Muco-adhesive, controlled release formulation of levodopa and/or esters of levodopa and uses thereof | 07 Oct, 2034 | Active |
| US8377474 | Controlled release formulations of levodopa and uses thereof | 26 Dec, 2028 | Active |
| US8454998 | Controlled release formulations of levodopa and uses thereof | 26 Dec, 2028 | Active |
| US8557283 | Controlled release formulations of levodopa and uses thereof | 26 Dec, 2028 | Active |
| US9089607 | Controlled release formulations of levodopa and uses thereof | 26 Dec, 2028 | Active |
| US9089608 | Controlled release formulations of levodopa and uses thereof | 26 Dec, 2028 | Active |
| US9463246 | Controlled release formulations of levodopa and uses thereof | 26 Dec, 2028 | Active |
| US9533046 | Controlled release formulations of levodopa and uses thereof | 26 Dec, 2028 | Active |
| US9901640 | Controlled release formulations of levodopa and uses thereof | 26 Dec, 2028 | Active |
| US7905352 | Kits containing medicine injection devices and containers | 12 Apr, 2027 | Active |
| US7621891 | Method and apparatus for delivering epinephrine | 04 Feb, 2025 | Expired |
| US10166334 | Medicine injection apparatuses | 21 Jan, 2025 | Expired |
| US10166344 | Injection needle assembly | 21 Jan, 2025 | Expired |
| US7297136 | Medicine injection devices and methods | 18 Jan, 2025 | Expired |
| US7094427 | Combination immediate release controlled release levodopa/carbidopa dosage forms | 29 May, 2022 | Expired |
| US5665071 | Reloadable automatic or manual emergency injection system | 27 May, 2013 | Expired |
Latest Legal Activities on Impax's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Impax.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 03 Jul, 2024 | US9533046 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 11 Apr, 2024 | US9463246 (Litigated) |
|
Email Notification
Critical
| 24 May, 2023 | US8377474 (Litigated) |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 24 May, 2023 | US8377474 (Litigated) |
| Payment of Maintenance Fee, 8th Year, Large Entity | 30 Jan, 2023 | US9089607 (Litigated) |
| Payment of Maintenance Fee, 8th Year, Large Entity | 30 Jan, 2023 | US9089608 (Litigated) |
| Payment of Maintenance Fee, 12th Year, Large Entity | 10 Aug, 2022 | US7905352 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 21 Jun, 2022 | US10166344 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 31 May, 2022 | US10166334 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 11 Aug, 2021 | US9901640 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 31 Mar, 2021 | US8557283 (Litigated) |
| Payment of Maintenance Fee, 12th Year, Large Entity | 18 Dec, 2020 | US7621891 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 18 Dec, 2020 | US7621891 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 25 Sep, 2020 | US8454998 (Litigated) |
| Payment of Maintenance Fee, 8th Year, Large Entity | 06 Aug, 2020 | US8377474 (Litigated) |
Impax Drug Patents' Oppositions Filed in EPO
Impax drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Jan 07, 2021, by Teva Pharmaceutical Industries Ltd.. This opposition was filed on patent number EP08866933A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
 | |||
| EP08866933A | Jan, 2021 | Luigi, Rumi | Granted and Under Opposition |
| EP08866933A | Jan, 2021 | Teva Pharmaceutical Industries Ltd. | Granted and Under Opposition |
Impax's Family Patents
Impax Drug List
Given below is the complete list of Impax's drugs and the patents protecting them.
1. Adrenaclick
Adrenaclick is protected by 4 patents, out of which 3 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7905352 | Kits containing medicine injection devices and containers |
12 Apr, 2027
(1 year, 10 months from now)
| Active |
| US10166334 | Medicine injection apparatuses |
21 Jan, 2025
(3 months ago)
| Expired |
| US10166344 | Injection needle assembly |
21 Jan, 2025
(3 months ago)
| Expired |
| US5665071 | Reloadable automatic or manual emergency injection system |
27 May, 2013
(11 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Adrenaclick's drug page
2. Crexont
Crexont is protected by 16 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11986449 | Levodopa dosing regimen |
21 Dec, 2041
(16 years from now)
| Active |
| US12109185 | Levodopa dosing regimen |
21 Dec, 2041
(16 years from now)
| Active |
| US12194150 | Levodopa dosing regimen |
21 Dec, 2041
(16 years from now)
| Active |
| US12201596 | Levodopa dosing regimen |
21 Dec, 2041
(16 years from now)
| Active |
| US10098845 | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof |
07 Oct, 2034
(9 years from now)
| Active |
| US10292935 | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof |
07 Oct, 2034
(9 years from now)
| Active |
| US10688058 | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof |
07 Oct, 2034
(9 years from now)
| Active |
| US10973769 | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof |
07 Oct, 2034
(9 years from now)
| Active |
| US10987313 | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof |
07 Oct, 2034
(9 years from now)
| Active |
| US11357733 | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof |
07 Oct, 2034
(9 years from now)
| Active |
| US11622941 | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof |
07 Oct, 2034
(9 years from now)
| Active |
| US11666538 | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof |
07 Oct, 2034
(9 years from now)
| Active |
| US12064521 | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof |
07 Oct, 2034
(9 years from now)
| Active |
| US12128141 | Muco-adhesive, controlled release formulation of levodopa and/or esters of levodopa and uses thereof |
07 Oct, 2034
(9 years from now)
| Active |
| US12178918 | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof |
07 Oct, 2034
(9 years from now)
| Active |
| US12178919 | Muco-adhesive, controlled release formulation of levodopa and/or esters of levodopa and uses thereof |
07 Oct, 2034
(9 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Crexont's drug page
3. Rytary
Rytary is protected by 9 patents, out of which 1 has expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8377474 | Controlled release formulations of levodopa and uses thereof |
26 Dec, 2028
(3 years from now)
| Active |
| US8454998 | Controlled release formulations of levodopa and uses thereof |
26 Dec, 2028
(3 years from now)
| Active |
| US8557283 | Controlled release formulations of levodopa and uses thereof |
26 Dec, 2028
(3 years from now)
| Active |
| US9089607 | Controlled release formulations of levodopa and uses thereof |
26 Dec, 2028
(3 years from now)
| Active |
| US9089608 | Controlled release formulations of levodopa and uses thereof |
26 Dec, 2028
(3 years from now)
| Active |
| US9463246 | Controlled release formulations of levodopa and uses thereof |
26 Dec, 2028
(3 years from now)
| Active |
| US9533046 | Controlled release formulations of levodopa and uses thereof |
26 Dec, 2028
(3 years from now)
| Active |
| US9901640 | Controlled release formulations of levodopa and uses thereof |
26 Dec, 2028
(3 years from now)
| Active |
| US7094427 | Combination immediate release controlled release levodopa/carbidopa dosage forms |
29 May, 2022
(2 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Rytary's drug page
4. Twinject 0.15
Twinject 0.15 is protected by 2 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7621891 | Method and apparatus for delivering epinephrine |
04 Feb, 2025
(3 months ago)
| Expired |
| US7297136 | Medicine injection devices and methods |
18 Jan, 2025
(3 months ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Twinject 0.15's drug page
5. Twinject 0.3
Twinject 0.3 is protected by 2 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7621891 | Method and apparatus for delivering epinephrine |
04 Feb, 2025
(3 months ago)
| Expired |
| US7297136 | Medicine injection devices and methods |
18 Jan, 2025
(3 months ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Twinject 0.3's drug page